NCT07821450Recruiting
Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study
Prospective Evaluation of Blepharoptosis Development in Patients Undergoing Repeated Intravitreal Anti-VEGF Injections
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
Intravitreal anti-VEGF injections are a mainstay of treatment for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and usually require repeated administration over years. During each injection an eyelid speculum holds the lids open and the upper eyelid is exposed to repeated mechanical stretch. Aponeurotic ptosis after intraocular surgery is well described, but evidence on blepharoptosis after repeated intravitreal injections is limited and conflicting. This single-center prospective observational study enrolls 60 patients who are starting intravitreal anti-VEGF therapy in one eye only; the untreated fellow eye of each patient serves as an internal control. Upper eyelid position and function are assessed with margin reflex distance-1 (MRD-1), margin reflex distance-2 (MRD-2) and levator function at baseline and at months 1, 3 and 6. The primary endpoint is the difference between the injected eye and the fellow eye in the change in MRD-1 from baseline to month 6.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 10 Sept 2026
- Start date
- 25 Sept 2026
- Primary completion date
- 25 Jun 2027
- Lead sponsor
- Abdulkadir Küçük
- Diseases
- Macular degeneration, Diabetic eye disease
- NCT number
- NCT07821450
What you commit to
- Study type: Observational
- Planned participants: 60
- From 25 Sept 2026 to the primary completion date, 25 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ptosis surgery, blepharoplasty or other eyelid surgery that may affect upper eyelid anatomy
- Ocular or periocular surgery during follow-up that may affect upper eyelid position
Other illness
- History of myasthenia gravis, oculomotor nerve palsy, Horner syndrome, facial nerve palsy or a similar neurologic or neuromuscular disorder
- History of orbital trauma, orbital surgery or orbital disease
Other
- Pre-existing blepharoptosis or significant eyelid malposition at the baseline examination
- Advanced dermatochalasis, eyelid retraction, entropion, ectropion or marked facial asymmetry precluding reliable eyelid measurement
- Need for intravitreal injection in both eyes during the study period
- Inability to comply with follow-up visits or incomplete measurements
- Withdrawal of consent
- Inability to obtain reliable eyelid measurements due to severe blepharospasm, advanced corneal opacity, marked eyelid edema, or inability to maintain head or neck position or to cooperate
Who the study is looking for
- Age 18 years or older
- Planned initiation of intravitreal anti-VEGF injection in one eye only for a retinal disease
- No prior intravitreal injection in either eye
- Able to attend the scheduled follow-up visits and to cooperate for the duration of the study
- Reliable MRD-1, MRD-2 and levator function measurement possible in both eyes (clear corneal light reflex, clearly visible eyelid margin, able to maintain primary gaze)
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.